EarningsQ4 2025 Earnings Report

Alnylam Pharma (DUL) Q4 2025 Earnings Report

4 Followers

DE:DUL Q4 2025 EPS Results

Actual EPS€0.73

Consensus EPS€1.03

Beat/MissMissed by -€0.29

One Year Ago EPS-€0.58

Actual Revenue€979.49M

Expected Revenue€1.03B

Beat/MissMissed by -€46.50M

YoY Revenue Growth+84.95%

QuarterQ4 2025

Date02/12/2026

TimeBefore Open

Conference CallThursday, February 12, 2026

DE:DUL Upcoming Earnings

Alnylam Pharma's next earnings date is estimated for February 18, 2027, based on past reporting schedules.

DE:DUL Q4 2025 Earnings Call

0:00 / 0:00

No earnings call summary is available for this earnings event.

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Feb 18, 2027	2026 (Q4)	1.56 / -	0.732	―
Oct 29, 2026	2026 (Q3)	1.48 / 14.04	1.643	754.35% (+12.39)
Jul 30, 2026	2026 (Q2)	1.46 / 1.08	-0.455	337.25% (+1.54)
Apr 30, 2026	2026 (Q1)	0.78 / 1.35	-0.393	443.18% (+1.74)
Feb 12, 2026	2025 (Q4)	1.03 / 0.73	-0.58	226.15% (+1.31)
Oct 30, 2025	2025 (Q3)	0.50 / 1.64	-0.777	311.49% (+2.42)
Jul 31, 2025	2025 (Q2)	-0.49 / -0.46	-0.116	-292.31% (-0.34)
May 01, 2025	2025 (Q1)	-0.79 / -0.39	-0.464	15.38% (+0.07)
Feb 13, 2025	2024 (Q4)	-0.53 / -0.58	-0.982	40.91% (+0.40)
Oct 31, 2024	2024 (Q3)	-0.82 / -0.78	1.027	-175.65% (-1.80)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed